Emricasan - Conatus Pharmaceuticals

Drug Profile

Emricasan - Conatus Pharmaceuticals

Alternative Names: Emricasan; IDN-6556; PF-03491390; PF-3,491,390; VAY 785

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idun Pharmaceuticals
  • Developer Conatus Pharmaceuticals
  • Class Amides; Aniline compounds; Antifibrotics; Antihypertensives; Fluorobenzenes; Hepatoprotectants; Pentanoic acids; Phenyl ethers; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Portal hypertension
  • Phase I/II Type 1 diabetes mellitus
  • Suspended Alcoholic hepatitis; Liver failure
  • No development reported Liver disorders
  • Discontinued Septic shock

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Apr 2018 Conatus Pharmaceuticals completes enrolment in the phase IIb ENCORE-PH trial for Portal hypertension and Non-alcoholic steatohepatitis in USA, Spain and Germany (NCT02960204)
  • 04 Apr 2018 Topline efficacy, adverse events and pharmacodynamic data from a phase IIb trial in Hepatic fibrosis released by Conatus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top